Responsiveness of endpoints in osteoporosis clinical trials.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 9195542.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The usefulness of an endpoint depends in part on its responsiveness to clinically important change. From existing randomized controlled trials, the responsiveness of endpoints currently employed in osteoporosis clinical trials were examined. The responsiveness is presented as the sample size per group needed to show a statistically significant difference. The large variation found means that careful attention needs to be given to the responsiveness of the population studied when estimating the sample size.
Medical subject headings
- Clinical Trials as Topic
- Osteoporosis